Trial Profile
A Single Center, Retrospective Study to Investigate Isavuconazole (ISA) as First-Line Primary Prophylaxis in Select Patients with Hematologic Malignancies and Hematopoietic Cell Transplant (HCT) Recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Nov 2018
Price :
$35
*
At a glance
- Drugs Isavuconazonium (Primary)
- Indications Aspergillosis; Mycoses
- Focus Therapeutic Use
- 11 Nov 2018 New trial record
- 07 Oct 2018 Results presented at the IDWeek 2018.